This Week in Neurosurgery — Oct 21, 2026
Generated Oct 22, 2026 · 11:26
The week's practice-changing Neurosurgery research, summarized for clinicians.
If the audio fails to play, refresh the page to renew the link.
Get next week’s Neurosurgery briefing — free.
In your podcast app, or readable in your inbox with the audio one tap away.
EGFR-targeted antibody-toxin conjugate in recurrent glioma: a phase 1 trial.
A single convection-enhanced infusion of the EGFR-targeted toxin D2C7 was generally well tolerated in recurrent glioma, with median survival near eight months and longer survival in biomarker-defined subgroups.
Nature Medicine · 2026 · PubMed
This week’s papers
- 01
EGFR-targeted antibody-toxin conjugate in recurrent glioma: a phase 1 trial.
A single convection-enhanced infusion of the EGFR-targeted toxin D2C7 was generally well tolerated in recurrent glioma, with median survival near eight months and longer survival in biomarker-defined subgroups.
Chandramohan V et al. · Nature Medicine · 2026
From the briefingWe open with glioma, where this week brings a novel therapy for recurrent glioblastoma and two papers on predicting who will be harmed by resection in deep, eloquent territory. In Nature Medicine, Chandramohan and colleagues report a single-site, open-label phase 1 trial of D2C7, an antibody-toxin conjugate aimed at both wild-type EGFR and the EGFR variant three mutant, given as a single infusion by convection-enhanced delivery directly into enhancing tumor in 81 patients with recurrent malignant glioma [1]. The recommended phase 2 concentration was 6,920 nanograms per millilitre; the maximum tolerated dose was exceeded at the top concentration, where four patients had dose-limiting grade 3 or 4 toxicity. Most treatment-related events were grade 1 or 2, and none of the eight on-trial deaths was attributed to the drug. Among the 72 patients with IDH wild-type recurrent glioblastoma, median survival was just under eight months, but biomarker subgroups did considerably better: patients with low pre-treatment tumor reactivity to the antibody, and those with low post-treatment plasma interleukin 8, had median survival of roughly sixteen to seventeen months. The authors argue the benefit flows through immune activation, but these are univariate, single-arm associations, so the trial establishes safety and a dose rather than efficacy.
If you only have time for one paper this week, make it the D2C7 trial in Nature Medicine [1]. It is a rare intratumoral, EGFR-directed therapy for recurrent glioblastoma to reach a defined phase 2 dose with acceptable safety, and its biomarker signals reopen the question of whether convection-enhanced delivery can benefit a selectable subset of patients.
Written by AI from the published abstract, for healthcare professionals. Not medical advice; check the paper before acting on it.
- 02
Basal forebrain glioma: Clinical characteristics and surgical treatment.
Basal forebrain glioma resection achieved seizure freedom in about 70 percent with mostly transient deficits, but posterior perforated substance extension lowered resection extent and raised morbidity risk.
Pitskhelauri D et al. · Journal of Clinical Neuroscience · 2026
From the briefingIn the Journal of Clinical Neuroscience, Pitskhelauri and colleagues describe 67 basal forebrain gliomas operated at the Burdenko Center through transsylvian, interhemispheric and subfrontal routes [2]. Median extent of resection was about 82 percent, and roughly 42 percent of patients with early imaging achieved at least 90 percent removal, though that fell to about a quarter when tumor extended into the posterior anterior perforated substance, versus about 60 percent otherwise. Hemiparesis followed in about one in eight patients and speech disturbance in just under a fifth, mostly from lenticulostriate injury, with speech usually improving by six months. Seizure freedom reached about 70 percent of patients with epilepsy, and was better above 70 percent resection. Extent of resection was not linked to survival in the whole cohort; only in a sensitivity analysis of grade 2 and 3 tumors did more resection track with longer survival, a borderline finding.
Written by AI from the published abstract, for healthcare professionals. Not medical advice; check the paper before acting on it.
- 03
Longitudinal motor recovery trajectories in brainstem glioma associated with preoperative DTI-based corticospinal tract involvement patterns.
Classifying brainstem gliomas by tractography as displacing, infiltrating or traversing the corticospinal tract separated distinct motor recovery trajectories and survival, offering a hypothesis-generating preoperative framework.
Zhang M et al. · Journal of Neuro-Oncology · 2026
From the briefingIn the Journal of Neuro-Oncology, Zhang and colleagues classified the corticospinal tract relationship in 180 brainstem gliomas on preoperative tractography as displacement, infiltration or traverse [3]. Displacement tumors were mostly low grade and recovered motor function quickly; traverse tumors were almost all high grade, showed minimal recovery and late decline, and had median survival of about a year, versus about fifteen months for infiltration, with median survival not reached for displacement. Reliability between raters was excellent, but the authors themselves frame the scheme as hypothesis-generating, and because tract pattern and tumor grade travel together, it is not yet clear how much the classification adds beyond biology.
Written by AI from the published abstract, for healthcare professionals. Not medical advice; check the paper before acting on it.
- 04
Long term outcomes and predictors of recurrence in central neurocytomas: a 35-year multi-institutional experience.
Central neurocytoma recurred frequently even after gross total resection, omitting adjuvant radiation predicted recurrence, and salvage radiation achieved durable control with ten-year survival of 94 percent.
Yang Y et al. · Journal of Neuro-Oncology · 2026
From the briefingStaying in neuro-oncology, a long-term series challenges assumptions about a rare ventricular tumor. Yang and colleagues, pooling 35 years of experience from Northwestern and Mayo Clinic in the Journal of Neuro-Oncology, followed 51 patients with central neurocytoma for a median of nearly ten years [4]. Ten-year survival was 94 percent, but recurrence was common even after gross total resection: without adjuvant radiation, five-year recurrence-free survival was about 61 percent after gross total and 46 percent after subtotal resection, a difference that was not statistically significant. On multivariable analysis, omitting adjuvant radiation was associated with roughly nine times the hazard of recurrence, and subtotal resection, younger age and higher Ki-67 also predicted recurrence. Salvage radiation at first recurrence gave durable control, with five-year recurrence-free survival over 80 percent. Given the small, retrospective cohort, the data reopen rather than settle the adjuvant-versus-salvage question.
Written by AI from the published abstract, for healthcare professionals. Not medical advice; check the paper before acting on it.
- 05
Rethinking the limits: SRS for ≥20 brain metastases with favorable brain and hippocampal doses.
Single-course radiosurgery for twenty or more brain metastases delivered lower mean brain and hippocampal doses than whole-brain approaches, with two probable radiation necrosis cases among twenty patients.
Ho A et al. · Journal of Clinical Neuroscience · 2026
From the briefingIn the Journal of Clinical Neuroscience, Ho and colleagues reviewed 20 patients who received single-course radiosurgery for 20 or more brain metastases, a median of 25 lesions per course [5]. Median mean brain dose was about 2.5 gray, below the 3 to 4 gray typical of whole-brain radiotherapy, and hippocampal dose was lower than with hippocampal-avoidant whole-brain treatment. Two patients developed probable radiation necrosis. This is a dosimetric study without cognitive or tumor-control endpoints, so it supports feasibility in selected patients rather than equivalence.
Written by AI from the published abstract, for healthcare professionals. Not medical advice; check the paper before acting on it.
- 06
Stereotactic body radiation therapy in elderly patients with spinal metastases.
In patients aged 70 and older, mostly single-fraction spine SBRT reirradiation yielded about 10 percent local failure at three years, with instability score, not age, predicting fracture.
Gjesdal BJ et al. · Journal of Neuro-Oncology · 2026
From the briefingIn the Journal of Neuro-Oncology, Gjesdal and colleagues analyzed 208 spinal metastases in 161 patients aged 70 to 94 treated with spine stereotactic body radiation, about three quarters of them as single-fraction reirradiation after prior conventional radiotherapy [6]. Local failure at three years was about 10 percent and compression fracture about 9 percent. Larger tumor volume and higher spinal instability scores predicted local failure, and instability alone predicted fracture, with most fractures needing cement or surgery. Age predicted overall survival but not local failure or fracture, at any threshold tested. Pain response was modest, at about 41 percent, and follow-up was short, but the authors conclude that chronologic age alone should not exclude elderly patients, with instability scoring the more relevant flag for surgical partners.
Written by AI from the published abstract, for healthcare professionals. Not medical advice; check the paper before acting on it.
- 07
Surgical management of spinal and sacral osteosarcoma: a retrospective single-institution case series.
Spinal and sacral osteosarcoma carried high recurrence and mortality despite multimodal therapy, but Enneking-appropriate resection was independently associated with better overall survival in 22 patients.
Khalilullah T et al. · Journal of Neurosurgery: Spine · 2026
From the briefingKhalilullah and colleagues report 22 patients with spinal and sacral osteosarcoma resected over a decade at a single tertiary center [7]. Despite neoadjuvant chemotherapy in most patients, just over half of patients had died at a median follow-up of nine months, local recurrence affected about 41 percent and distant metastasis about a third. Enneking-appropriate resection was independently associated with better survival, while older age, non-conventional histology and mobile spine location predicted worse survival. The numbers are small, but the series reinforces the margin principle for this tumor.
Written by AI from the published abstract, for healthcare professionals. Not medical advice; check the paper before acting on it.
- 08
Clinical outcomes of nonambulatory patients caused by ossification of the ligamentum flavum in the thoracic spine.
About 81 percent of nonambulatory patients with thoracic ligamentum flavum ossification walked again after posterior decompression and fusion; female sex and worse baseline function predicted failure.
Lei J et al. · Journal of Neurosurgery: Spine · 2026
From the briefingLei and colleagues studied 72 patients who could not walk at all before posterior decompression and fusion for thoracic ossification of the ligamentum flavum, all with at least two years of follow-up [8]. About four in five patients regained ambulation, independently or with aids, and neurological scores improved significantly. Female sex was linked to roughly four and a half times the odds of remaining nonambulatory, and worse preoperative function also predicted failure. This retrospective series suggests that loss of ambulation by itself does not place these patients beyond meaningful recovery.
Written by AI from the published abstract, for healthcare professionals. Not medical advice; check the paper before acting on it.
- 09
Combining responsive neurostimulation with resection or ablation for treatment of epilepsy: a multicenter experience.
Combining responsive neurostimulation with resection or laser ablation in complex drug-resistant epilepsy reduced seizures by roughly half to two thirds at one year, with acceptable safety, in uncontrolled data.
Lopez Ramos CG et al. · Journal of Neurosurgery · 2026
From the briefingIn the Journal of Neurosurgery, Lopez Ramos and colleagues pooled 73 patients from nine centers who received responsive neurostimulation combined with resection or laser ablation, usually on the same day, mostly because seizure onset involved eloquent cortex or multiple foci [9]. At one year, mean seizure reduction was roughly one half to two thirds depending on seizure type, just under half of patients had at least six months of seizure freedom, and about four in five were rated much or very much improved. Three patients had infections. Without a comparison group, this describes current practice and supports formal study of hybrid strategies rather than establishing superiority.
Written by AI from the published abstract, for healthcare professionals. Not medical advice; check the paper before acting on it.
- 10
Spatial localization patterns in MRI-negative Cushing disease: a comparative pituitary heat map analysis.
MRI-negative corticotroph adenomas lacked the lateral and dorsal clustering of visible tumors and needed reoperation more often, while lower remission rates did not reach statistical significance.
Chung RJ et al. · Journal of Neurosurgery · 2026
From the briefingAlso in the Journal of Neurosurgery, Chung and colleagues mapped intraoperative sketches of 153 histologically confirmed corticotroph adenomas resected by the late Oldfield [10]. MRI-positive tumors clustered in the lateral and dorsal anterior gland, whereas MRI-negative tumors showed no favored region. Patients with MRI-negative disease had higher postoperative cortisol nadirs and about a fifth needed reoperation, versus about four percent of MRI-positive patients; remission was lower, 75 versus 91 percent, but that difference did not reach statistical significance. With only 20 MRI-negative cases from a single surgeon, the authors caution that intraoperative findings should still drive exploration.
Written by AI from the published abstract, for healthcare professionals. Not medical advice; check the paper before acting on it.
The full briefing
This AudioScholar briefing is generated by artificial intelligence for healthcare professionals and trainees. It is not medical advice.
Welcome to This Week in Neurosurgery. This week we're covering 10 notable papers spanning new strategies and surgical risk mapping in brain tumors, radiation as an alternative or partner to surgery, spine surgery for rare and severe disease, and operating when the target is hard to find. Let's dive in.
We open with glioma, where this week brings a novel therapy for recurrent glioblastoma and two papers on predicting who will be harmed by resection in deep, eloquent territory. In Nature Medicine, Chandramohan and colleagues report a single-site, open-label phase 1 trial of D2C7, an antibody-toxin conjugate aimed at both wild-type EGFR and the EGFR variant three mutant, given as a single infusion by convection-enhanced delivery directly into enhancing tumor in 81 patients with recurrent malignant glioma [1]. The recommended phase 2 concentration was 6,920 nanograms per millilitre; the maximum tolerated dose was exceeded at the top concentration, where four patients had dose-limiting grade 3 or 4 toxicity. Most treatment-related events were grade 1 or 2, and none of the eight on-trial deaths was attributed to the drug. Among the 72 patients with IDH wild-type recurrent glioblastoma, median survival was just under eight months, but biomarker subgroups did considerably better: patients with low pre-treatment tumor reactivity to the antibody, and those with low post-treatment plasma interleukin 8, had median survival of roughly sixteen to seventeen months. The authors argue the benefit flows through immune activation, but these are univariate, single-arm associations, so the trial establishes safety and a dose rather than efficacy. Two surgical series address where the line of acceptable morbidity sits. In the Journal of Clinical Neuroscience, Pitskhelauri and colleagues describe 67 basal forebrain gliomas operated at the Burdenko Center through transsylvian, interhemispheric and subfrontal routes [2]. Median extent of resection was about 82 percent, and roughly 42 percent of patients with early imaging achieved at least 90 percent removal, though that fell to about a quarter when tumor extended into the posterior anterior perforated substance, versus about 60 percent otherwise. Hemiparesis followed in about one in eight patients and speech disturbance in just under a fifth, mostly from lenticulostriate injury, with speech usually improving by six months. Seizure freedom reached about 70 percent of patients with epilepsy, and was better above 70 percent resection. Extent of resection was not linked to survival in the whole cohort; only in a sensitivity analysis of grade 2 and 3 tumors did more resection track with longer survival, a borderline finding. In the Journal of Neuro-Oncology, Zhang and colleagues classified the corticospinal tract relationship in 180 brainstem gliomas on preoperative tractography as displacement, infiltration or traverse [3]. Displacement tumors were mostly low grade and recovered motor function quickly; traverse tumors were almost all high grade, showed minimal recovery and late decline, and had median survival of about a year, versus about fifteen months for infiltration, with median survival not reached for displacement. Reliability between raters was excellent, but the authors themselves frame the scheme as hypothesis-generating, and because tract pattern and tumor grade travel together, it is not yet clear how much the classification adds beyond biology.
Staying in neuro-oncology, a long-term series challenges assumptions about a rare ventricular tumor. Yang and colleagues, pooling 35 years of experience from Northwestern and Mayo Clinic in the Journal of Neuro-Oncology, followed 51 patients with central neurocytoma for a median of nearly ten years [4]. Ten-year survival was 94 percent, but recurrence was common even after gross total resection: without adjuvant radiation, five-year recurrence-free survival was about 61 percent after gross total and 46 percent after subtotal resection, a difference that was not statistically significant. On multivariable analysis, omitting adjuvant radiation was associated with roughly nine times the hazard of recurrence, and subtotal resection, younger age and higher Ki-67 also predicted recurrence. Salvage radiation at first recurrence gave durable control, with five-year recurrence-free survival over 80 percent. Given the small, retrospective cohort, the data reopen rather than settle the adjuvant-versus-salvage question.
Our next theme is radiation pushing into territory once reserved for whole-brain treatment or surgery. In the Journal of Clinical Neuroscience, Ho and colleagues reviewed 20 patients who received single-course radiosurgery for 20 or more brain metastases, a median of 25 lesions per course [5]. Median mean brain dose was about 2.5 gray, below the 3 to 4 gray typical of whole-brain radiotherapy, and hippocampal dose was lower than with hippocampal-avoidant whole-brain treatment. Two patients developed probable radiation necrosis. This is a dosimetric study without cognitive or tumor-control endpoints, so it supports feasibility in selected patients rather than equivalence. In the Journal of Neuro-Oncology, Gjesdal and colleagues analyzed 208 spinal metastases in 161 patients aged 70 to 94 treated with spine stereotactic body radiation, about three quarters of them as single-fraction reirradiation after prior conventional radiotherapy [6]. Local failure at three years was about 10 percent and compression fracture about 9 percent. Larger tumor volume and higher spinal instability scores predicted local failure, and instability alone predicted fracture, with most fractures needing cement or surgery. Age predicted overall survival but not local failure or fracture, at any threshold tested. Pain response was modest, at about 41 percent, and follow-up was short, but the authors conclude that chronologic age alone should not exclude elderly patients, with instability scoring the more relevant flag for surgical partners.
Two spine papers in the Journal of Neurosurgery: Spine examine the extremes of surgical disease. Khalilullah and colleagues report 22 patients with spinal and sacral osteosarcoma resected over a decade at a single tertiary center [7]. Despite neoadjuvant chemotherapy in most patients, just over half of patients had died at a median follow-up of nine months, local recurrence affected about 41 percent and distant metastasis about a third. Enneking-appropriate resection was independently associated with better survival, while older age, non-conventional histology and mobile spine location predicted worse survival. The numbers are small, but the series reinforces the margin principle for this tumor. Lei and colleagues studied 72 patients who could not walk at all before posterior decompression and fusion for thoracic ossification of the ligamentum flavum, all with at least two years of follow-up [8]. About four in five patients regained ambulation, independently or with aids, and neurological scores improved significantly. Female sex was linked to roughly four and a half times the odds of remaining nonambulatory, and worse preoperative function also predicted failure. This retrospective series suggests that loss of ambulation by itself does not place these patients beyond meaningful recovery.
Our final theme is surgery when the target is diffuse or invisible. In the Journal of Neurosurgery, Lopez Ramos and colleagues pooled 73 patients from nine centers who received responsive neurostimulation combined with resection or laser ablation, usually on the same day, mostly because seizure onset involved eloquent cortex or multiple foci [9]. At one year, mean seizure reduction was roughly one half to two thirds depending on seizure type, just under half of patients had at least six months of seizure freedom, and about four in five were rated much or very much improved. Three patients had infections. Without a comparison group, this describes current practice and supports formal study of hybrid strategies rather than establishing superiority. Also in the Journal of Neurosurgery, Chung and colleagues mapped intraoperative sketches of 153 histologically confirmed corticotroph adenomas resected by the late Oldfield [10]. MRI-positive tumors clustered in the lateral and dorsal anterior gland, whereas MRI-negative tumors showed no favored region. Patients with MRI-negative disease had higher postoperative cortisol nadirs and about a fifth needed reoperation, versus about four percent of MRI-positive patients; remission was lower, 75 versus 91 percent, but that difference did not reach statistical significance. With only 20 MRI-negative cases from a single surgeon, the authors caution that intraoperative findings should still drive exploration.
If you only have time for one paper this week, make it the D2C7 trial in Nature Medicine [1]. It is a rare intratumoral, EGFR-directed therapy for recurrent glioblastoma to reach a defined phase 2 dose with acceptable safety, and its biomarker signals reopen the question of whether convection-enhanced delivery can benefit a selectable subset of patients.
Here is what this week's evidence adds up to in Neurosurgery. First, convection-enhanced D2C7 is safe enough to move forward in recurrent glioblastoma, but efficacy remains unproven and the survival-linked biomarkers need prospective validation. Second, deep glioma surgery is increasingly risk-stratified by anatomy, with posterior perforated substance involvement and corticospinal tract traversal marking higher morbidity, though both systems come from single-center retrospective work. Third, radiation is expanding: retrospective data support radiosurgery for very high metastasis counts on dosimetric grounds and spine stereotactic radiation in older patients regardless of age, while instability scores identify patients at risk of fracture. Fourth, in spine surgery, margin-appropriate resection tracks with survival in osteosarcoma, and even nonambulatory patients with thoracic ligamentum flavum ossification often walk again after decompression. Finally, neurocytoma recurs more often after complete resection than previously assumed, and both hybrid epilepsy surgery and anatomical mapping in MRI-negative Cushing disease remain early, uncontrolled evidence.
That's your roundup for This Week in Neurosurgery. The full transcript and references are available on the episode page. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week.
If this weekly briefing is useful, follow the show in your podcast app so new episodes arrive automatically. And think of one colleague — in any specialty — who never has time to keep up with the literature. Tell them about AudioScholar: a free ten-minute weekly for every specialty, to listen to in any podcast app, or to read at audioscholar dot C C.
This is an automated summary generated by artificial intelligence, which can make mistakes. Always review the original source materials.
Spot something worth flagging?
Get this every week in your podcast app — free.
New neurosurgery episodes land in your feed automatically — listen on your commute.